February 25, 2014 8:47 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: RARE) with an Overweight rating and $81.00 price target.In the report, Morgan Stanley noted, “Ultragenyx is an orphan disease focused co. that has in-licensed a series of interesting early/mid stage drugs. The current in-licensing model mitigates some of the high spend and clinical risk in drug discovery, setting the co. up ideally to have solid profitability. We currently view KRN23 and triheptanoin as key value drivers within the current pipeline, and expect business dev't to expand the pipeline with time. Importantly, while our risk/reward framework implies both sig. upside and downside are possible vs. the current stock price and our PT, we view the bear case (no drug success from the current pipeline) as very unlikely. This low probability skews the risk/reward sig. upwards.”Ultragenyx Pharmaceutical closed on Monday at $58.01.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.